Person Profile

Prof. Yuri Volkov received his MD from the Moscow Medical University and subsequently a PhD in biomedical sciences at the Institute of Immunology, Moscow. He has been working at the Department of Clinical Medicine, Trinity College Dublin since 1995. His research interests for a number of years have been focused in leukocyte biology, mechanisms of inflammation and cell adhesion receptors functioning in immune defence and disease development. Among the main achievements in this area was the discovery and characterization of the crucial impact of intracellular phosphorylation enzyme of the protein kinase C family - PKC-beta for the process of T cell migration. Success of these studies has been made possible through the implementation of the cutting edge High Content Screening Analysis (HCSA) cell and molecular imaging technologies. As a Principal Investigator at the Institute of Molecular Medicine, Prof. Volkov has made a key contribution into establishing of the HCSA Centre in Trinity College which represents a state-of-the art facility in the academic institution at the international level. Prof. Volkov has formed a large-scale interdisciplinary alliance between the Schools of Medicine, Physics, and Chemistry at Trinity College aimed at the development of new nanoscale molecular imaging and drug delivery systems. Prof. Volkov is also a Principal Investigator at the Trinity College's Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN), where his group is pursuing the applications of nanomaterials for advanced research and medical diagnostics. Prof. Volkov currently coordinates a large scale EU FP-7 funded Consortium "NAMDIATREAM" (www. namdiatream.eu) which unites the expertise of 22 European academic, research, clinical and industrial partners towards the development of nanotechnological toolkits for early diagnostics and treatment monitoring of major types of cancer. He is also a Lead TCD partner for EU FP-7 LSP "MULTIFUN" and "Celtic Alliance for Nanohealth" Ireland-Wales INTERREG Consortium.Prof. Yuri Volkov received his MD from the Moscow Medical University and subsequently a PhD in biomedical sciences at the Institute of Immunology, Moscow. He has been working at the Department of Clinical Medicine, Trinity College Dublin since 1995. His research interests for a number of years have been focused in leukocyte biology, mechanisms of inflammation and cell adhesion receptors functioning in immune defence and disease development. Among the main achievements in this area was the discovery and characterization of the crucial impact of intracellular phosphorylation enzyme of the protein kinase C family - PKC-beta for the process of T cell migration. Success of these studies has been made possible through the implementation of the cutting edge High Content Screening Analysis (HCSA) cell and molecular imaging technologies. As a Principal Investigator at the Institute of Molecular Medicine, Prof. Volkov has made a key contribution into establishing of the HCSA Centre in Trinity College which represents a state-of-the art facility in the academic institution at the international level. Prof. Volkov has formed a large-scale interdisciplinary alliance between the Schools of Medicine, Physics, and Chemistry at Trinity College aimed at the development of new nanoscale molecular imaging and drug delivery systems. Prof. Volkov is also a Principal Investigator at the Trinity College's Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN), where his group is pursuing the applications of nanomaterials for advanced research and medical diagnostics. Prof. Volkov currently coordinates a large scale EU FP-7 funded Consortium "NAMDIATREAM" (www. namdiatream.eu) which unites the expertise of 22 European academic, research, clinical and industrial partners towards the development of nanotechnological toolkits for early diagnostics and treatment monitoring of major types of cancer. He is also a Lead TCD partner for EU FP-7 LSP "MULTIFUN" and "Celtic Alliance for Nanohealth" Ireland-Wales INTERREG Consortium.Prof. Yuri Volkov received his MD from the Moscow Medical University and subsequently a PhD in biomedical sciences at the Institute of Immunology, Moscow. He has been working at the Department of Clinical Medicine, Trinity College Dublin since 1995. His research interests for a number of years have been focused in leukocyte biology, mechanisms of inflammation and cell adhesion receptors functioning in immune defence and disease development. Among the main achievements in this area was the discovery and characterization of the crucial impact of intracellular phosphorylation enzyme of the protein kinase C family - PKC-beta for the process of T cell migration. Success of these studies has been made possible through the implementation of the cutting edge High Content Screening Analysis (HCSA) cell and molecular imaging technologies. As a Principal Investigator at the Institute of Molecular Medicine, Prof. Volkov has made a key contribution into establishing of the HCSA Centre in Trinity College which represents a state-of-the art facility in the academic institution at the international level. Prof. Volkov has formed a large-scale interdisciplinary alliance between the Schools of Medicine, Physics, and Chemistry at Trinity College aimed at the development of new nanoscale molecular imaging and drug delivery systems. Prof. Volkov is also a Principal Investigator at the Trinity College's Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN), where his group is pursuing the applications of nanomaterials for advanced research and medical diagnostics. Prof. Volkov currently coordinates a large scale EU FP-7 funded Consortium "NAMDIATREAM" (www. namdiatream.eu) which unites the expertise of 22 European academic, research, clinical and industrial partners towards the development of nanotechnological toolkits for early diagnostics and treatment monitoring of major types of cancer. He is also a Lead TCD partner for EU FP-7 LSP "MULTIFUN" and "Celtic Alliance for Nanohealth" Ireland-Wales INTERREG Consortium.Prof. Yuri Volkov received his MD from the Moscow Medical University and subsequently a PhD in biomedical sciences at the Institute of Immunology, Moscow. He has been working at the Department of Clinical Medicine, Trinity College Dublin since 1995. His research interests for a number of years have been focused in leukocyte biology, mechanisms of inflammation and cell adhesion receptors functioning in immune defence and disease development. Among the main achievements in this area was the discovery and characterization of the crucial impact of intracellular phosphorylation enzyme of the protein kinase C family - PKC-beta for the process of T cell migration. Success of these studies has been made possible through the implementation of the cutting edge High Content Screening Analysis (HCSA) cell and molecular imaging technologies. As a Principal Investigator at the Institute of Molecular Medicine, Prof. Volkov has made a key contribution into establishing of the HCSA Centre in Trinity College which represents a state-of-the art facility in the academic institution at the international level. Prof. Volkov has formed a large-scale interdisciplinary alliance between the Schools of Medicine, Physics, and Chemistry at Trinity College aimed at the development of new nanoscale molecular imaging and drug delivery systems. Prof. Volkov is also a Principal Investigator at the Trinity College's Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN), where his group is pursuing the applications of nanomaterials for advanced research and medical diagnostics. Prof. Volkov currently coordinates a large scale EU FP-7 funded Consortium "NAMDIATREAM" (www. namdiatream.eu) which unites the expertise of 22 European academic, research, clinical and industrial partners towards the development of nanotechnological toolkits for early diagnostics and treatment monitoring of major types of cancer. He is also a Lead TCD partner for EU FP-7 LSP "MULTIFUN" and "Celtic Alliance for Nanohealth" Ireland-Wales INTERREG Consortium.Prof. Yuri Volkov received his MD from the Moscow Medical University and subsequently a PhD in biomedical sciences at the Institute of Immunology, Moscow. He has been working at the Department of Clinical Medicine, Trinity College Dublin since 1995. His research interests for a number of years have been focused in leukocyte biology, mechanisms of inflammation and cell adhesion receptors functioning in immune defence and disease development. Among the main achievements in this area was the discovery and characterization of the crucial impact of intracellular phosphorylation enzyme of the protein kinase C family - PKC-beta for the process of T cell migration. Success of these studies has been made possible through the implementation of the cutting edge High Content Screening Analysis (HCSA) cell and molecular imaging technologies. As a Principal Investigator at the Institute of Molecular Medicine, Prof. Volkov has made a key contribution into establishing of the HCSA Centre in Trinity College which represents a state-of-the art facility in the academic institution at the international level. Prof. Volkov has formed a large-scale interdisciplinary alliance between the Schools of Medicine, Physics, and Chemistry at Trinity College aimed at the development of new nanoscale molecular imaging and drug delivery systems. Prof. Volkov is also a Principal Investigator at the Trinity College's Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN), where his group is pursuing the applications of nanomaterials for advanced research and medical diagnostics. Prof. Volkov currently coordinates a large scale EU FP-7 funded Consortium "NAMDIATREAM" (www. namdiatream.eu) which unites the expertise of 22 European academic, research, clinical and industrial partners towards the development of nanotechnological toolkits for early diagnostics and treatment monitoring of major types of cancer. He is also a Lead TCD partner for EU FP-7 LSP "MULTIFUN" and "Celtic Alliance for Nanohealth" Ireland-Wales INTERREG Consortium.Prof. Yuri Volkov received his MD from the Moscow Medical University and subsequently a PhD in biomedical sciences at the Institute of Immunology, Moscow. He has been working at the Department of Clinical Medicine, Trinity College Dublin since 1995. His research interests for a number of years have been focused in leukocyte biology, mechanisms of inflammation and cell adhesion receptors functioning in immune defence and disease development. Among the main achievements in this area was the discovery and characterization of the crucial impact of intracellular phosphorylation enzyme of the protein kinase C family - PKC-beta for the process of T cell migration. Success of these studies has been made possible through the implementation of the cutting edge High Content Screening Analysis (HCSA) cell and molecular imaging technologies. As a Principal Investigator at the Institute of Molecular Medicine, Prof. Volkov has made a key contribution into establishing of the HCSA Centre in Trinity College which represents a state-of-the art facility in the academic institution at the international level. Prof. Volkov has formed a large-scale interdisciplinary alliance between the Schools of Medicine, Physics, and Chemistry at Trinity College aimed at the development of new nanoscale molecular imaging and drug delivery systems. Prof. Volkov is also a Principal Investigator at the Trinity College's Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN), where his group is pursuing the applications of nanomaterials for advanced research and medical diagnostics. Prof. Volkov currently coordinates a large scale EU FP-7 funded Consortium "NAMDIATREAM" (www. namdiatream.eu) which unites the expertise of 22 European academic, research, clinical and industrial partners towards the development of nanotechnological toolkits for early diagnostics and treatment monitoring of major types of cancer. He is also a Lead TCD partner for EU FP-7 LSP "MULTIFUN" and "Celtic Alliance for Nanohealth" Ireland-Wales INTERREG Consortium.Prof. Yuri Volkov received his MD from the Moscow Medical University and subsequently a PhD in biomedical sciences at the Institute of Immunology, Moscow. He has been working at the Department of Clinical Medicine, Trinity College Dublin since 1995. His research interests for a number of years have been focused in leukocyte biology, mechanisms of inflammation and cell adhesion receptors functioning in immune defence and disease development. Among the main achievements in this area was the discovery and characterization of the crucial impact of intracellular phosphorylation enzyme of the protein kinase C family - PKC-beta for the process of T cell migration. Success of these studies has been made possible through the implementation of the cutting edge High Content Screening Analysis (HCSA) cell and molecular imaging technologies. As a Principal Investigator at the Institute of Molecular Medicine, Prof. Volkov has made a key contribution into establishing of the HCSA Centre in Trinity College which represents a state-of-the art facility in the academic institution at the international level. Prof. Volkov has formed a large-scale interdisciplinary alliance between the Schools of Medicine, Physics, and Chemistry at Trinity College aimed at the development of new nanoscale molecular imaging and drug delivery systems. Prof. Volkov is also a Principal Investigator at the Trinity College's Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN), where his group is pursuing the applications of nanomaterials for advanced research and medical diagnostics. Prof. Volkov currently coordinates a large scale EU FP-7 funded Consortium "NAMDIATREAM" (www. namdiatream.eu) which unites the expertise of 22 European academic, research, clinical and industrial partners towards the development of nanotechnological toolkits for early diagnostics and treatment monitoring of major types of cancer. He is also a Lead TCD partner for EU FP-7 LSP "MULTIFUN" and "Celtic Alliance for Nanohealth" Ireland-Wales INTERREG Consortium.

Publications

  1. 2Kolesova E.P., Maslov V.G., Safin F.M., Finn P., Cleary O., Volkov Y., Gun’ko Y.K., Orlova A.O. Photoinduced Charge Transfer in Hybrid Structures Based on Titanium Dioxide NPs with Multicomponent QD Exciton Luminescence Decay // Journal of Physical Chemistry C - 2019, Vol. 123, No. 23, pp. 14790-14796 [IF: 4.536, SJR: 1.652]
    more >>
  2. 1Hutchinson D., Muller J., Mccarthy J.E., Gun’ko Y.K., Verma N.K., Bi X., Di Cristo L., Kickham L., Movia D., Prina-Mello A., Volkov Y. Cadmium nanoparticles citrullinate cytokeratins within lung epithelial cells: Cadmium as a potential cause of citrullination in chronic obstructive pulmonary disease // International Journal of Chronic Obstructive Pulmonary Disease - 2018, Vol. 13, pp. 441-449 [IF: 3.157, SJR: 1.424]
    more >>